FERMION OY Patent applications |
Patent application number | Title | Published |
20150321983 | A PROCESS FOR THE PREPARATION OF OSPEMIFENE - The present invention is related to the process for the preparation ospemifene or (Z)-2[4-(4-chloro-1,2-diphen-yl-but-1-enyl)phenoxy]ethanol (I) and to intermediate compounds used in the process. | 11-12-2015 |
20150274624 | PROCESS FOR THE PREPARATION OF OSPEMIFENE - The present invention is related to the process for the preparation ospemifene or (Z)-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol (I) and to intermediate compounds used in the process. | 10-01-2015 |
20110112290 | PROCESS FOR THE PREPARATION OF QUETIAPINE - The invention relates to a method for the preparation of 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo[b,f]-1,4-thiazepine and pharmaceutically acceptable salts thereof comprising the reaction of 1-[2-(hydroxyethoxy)-ethyl]piperazine with dibenzo[b,f][1,4]thiazepin-11-ylamine. | 05-12-2011 |
20090156802 | Quetiapine Hemifumarate Purification by Crystallization - The present invention relates to a process for preparing and purifying crystalline quetiapine hemifumarate, which comprises preparing crystalline quetiapine hemifumarate via a crystalline salt, which is not a salt of fumaric acid. | 06-18-2009 |
20090137844 | Crystallization process - The invention relates to a process for the production of tamsulosin hydrochloride crystals where the crystal size distribution is controlled by controlling the temperature where hydrochloric acid is added to the reaction mixture. | 05-28-2009 |
20090082597 | PROCESS FOR PREPARING A COMPOUND - The invention relates to the use of copper-catalyzed nucleophilic aromatic substitution reaction for preparing 3-aryloxy-3-arylpropylamines and more specifically to a method of preparing certain 3-aryloxy-3-arylpropylamines and the pharmaceutically acceptable addition salts thereof, comprising reacting an amino alcohol with a haloaromatic compound in the presence of a base and a catalytic copper source, and in the absence of a separate ligand. | 03-26-2009 |